Vinge has advised XVIVO in conjunction with its directed share issue of SEK 440 million.

September 14, 2023 M&A

Vinge has advised XVIVO Perfusion AB in connection with its directed share issue at a subscription price of SEK 275 per share which corresponded to the closing price of XVIVO’s shares on Nasdaq Stockholm on the day of the issue.

XVIVO received SEK 440 million before issue costs. The subscription price was determined through an accelerated bookbuilding procedure arranged by Carnegie and DNB Markets. Investors in the directed share issue were both existing and new shareholders such as Bure Equity AB, the Fourth Swedish National Pension Fund, Swedbank Robur Fonder, Eccenovo, Handelsbanken Fonder, Tredje AP-fonden and a Tier-1 global international investor.

Vinge's team primarily consisted of Anders Strid and project manager Edin Agic.



Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023